BioLine RX (Israel) Today

BLRX Stock  ILS 1.60  0.10  6.67%   

Performance

Weakest

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
BioLine RX is trading at 1.60 as of the 29th of January 2026, a 6.67 percent increase since the beginning of the trading day. The stock's open price was 1.5. BioLine RX has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 31st of October 2025 and ending today, the 29th of January 2026. Click here to learn more.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. The company has 922.87 M outstanding shares. More on BioLine RX

Moving together with BioLine Stock

  0.86TMRP Tamar PetroleumPairCorr

Moving against BioLine Stock

  0.89ZUR Zur Shamir HoldingsPairCorr
  0.82ELAL El Al IsraelPairCorr
  0.82KNFM KnafaimPairCorr
  0.75MRHL Merchavia Holdings andPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

BioLine Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BioLine RX's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BioLine RX or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Vice President - DevelopmentElla Sorani
Business ConcentrationHealth Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
BioLine RX (BLRX) is traded on Tel Aviv Stock Exchange in Israel and employs 38 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 135.72 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioLine RX's market, we take the total number of its shares issued and multiply it by BioLine RX's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BioLine RX operates under Biotechnology sector and is part of Health Care industry. The entity has 922.87 M outstanding shares. BioLine RX has accumulated about 40.61 M in cash with (23.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28.
Check BioLine RX Probability Of Bankruptcy
Ownership Allocation
BioLine RX holds a total of 922.87 Million outstanding shares. Almost 99.65 percent of BioLine RX outstanding shares are held by general public with 0.25 (percent) owned by insiders and only 0.1 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioLine Ownership Details

BioLine RX Risk Profiles

Although BioLine RX's alpha and beta are two of the key measurements used to evaluate BioLine RX's performance over the market, the standard measures of volatility play an important role as well.

BioLine Stock Against Markets

BioLine Stock Analysis Notes

The company has price-to-book (P/B) ratio of 0.77. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioLine RX recorded a loss per share of 0.03. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 7th of June 2015. BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people. For more info on BioLine RX please contact the company at (972) 8 642 9101 or go to www.biolinerx.com.

BioLine RX Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. BioLine RX's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding BioLine RX or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
BioLine RX generated a negative expected return over the last 90 days
BioLine RX may become a speculative penny stock
BioLine RX has high historical volatility and very poor performance
Net Loss for the year was (27.05 M) with profit before overhead, payroll, taxes, and interest of 0.
BioLine RX has accumulated about 40.61 M in cash with (23.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28.

BioLine Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 135.72 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioLine RX's market, we take the total number of its shares issued and multiply it by BioLine RX's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Technical Drivers

As of the 29th of January, BioLine RX shows the Risk Adjusted Performance of (0.07), standard deviation of 4.41, and Mean Deviation of 3.14. BioLine RX technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

BioLine RX Price Movement Analysis

Transformation
The output start index for this execution was zero with a total number of output elements of sixty-one. BioLine RX Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe BioLine RX price patterns.

BioLine RX Outstanding Bonds

BioLine RX issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioLine RX uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioLine bonds can be classified according to their maturity, which is the date when BioLine RX has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

BioLine RX Predictive Daily Indicators

BioLine RX intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioLine RX stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

BioLine RX Forecast Models

BioLine RX's time-series forecasting models are one of many BioLine RX's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioLine RX's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Be your own money manager

Our tools can tell you how much better you can do entering a position in BioLine RX without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Analyzer Now

   

Portfolio Analyzer

Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
All  Next Launch Module

BioLine RX Corporate Management

Elected by the shareholders, the BioLine RX's board of directors comprises two types of representatives: BioLine RX inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLine. The board's role is to monitor BioLine RX's management team and ensure that shareholders' interests are well served. BioLine RX's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLine RX's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPAChief OfficerProfile
Raziel FriedTreasurer DirectorProfile
Jael MScQA RAProfile
CPA MBAChief OfficerProfile
Holly MBAPres USAProfile
Advocate KotlerGen OfficerProfile

Other Information on Investing in BioLine Stock

BioLine RX financial ratios help investors to determine whether BioLine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLine with respect to the benefits of owning BioLine RX security.